Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease
- 29 March 2022
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 34 (6) , 613-621
Abstract
Objective: Gastrointestinal ultrasound (GIUS) accurately assesses inflammation and is responsive to changes in inflammatory bowel disease. This study aimed to determine the prognostic utility of sonographic response in the first 14 weeks of a newly-instituted therapy with therapeutic response at 46 weeks and to compare its performance with standard clinical assessment tools. Methods: Patients with sonographic evidence of inflammation were assessed by GIUS, clinical activity, serum C-reactive protein and faecal calprotectin again 2, 6 and 14 weeks after commencing a new biologic or thiopurine. Treatment failure was defined as undergoing surgery, hospitalisation, escalation of dosage or introduction of new medication over 46-weeks’ follow-up. Sonographic response was defined as a decrease in bowel wall thickness and improved vascularity. Results: In 31 patients (median age 49 years, 74% Crohn’s disease), sonographic response at 14 weeks [OR 19.3, 95% confidence interval (CI), 3.23–101.10; P = 0.0054] and faecal calprotectin (P = 0.018), but no clinical disease activity or C-reactive protein, were predictive of subsequent treatment response. Sonographic response alone was predictive at week 6 (P = 0.016), but not week 2. 16% reduction in bowel wall thickness at 6 weeks (area-under-the-receiver-operator-curve=0.86; P = 0.002; sensitivity 72%, specificity 90%), with similar performance for 10% at 14 weeks, was associated with treatment response. Conclusion: Sonographic response as early as 6 weeks after initiation of a new therapy may accurately predict treatment outcomes over 46 weeks and is superior to other markers used to monitor disease activity.Keywords
This publication has 46 references indexed in Scilit:
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's diseaseScandinavian Journal of Gastroenterology, 2012
- Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2011
- Abdominal Sonographic Changes After Antibody to Tumor Necrosis Factor (Anti-TNF) Alpha Therapy in Crohn’s DiseaseDigestive Diseases and Sciences, 2009
- Predicting the clinical response to cytapheresis in steroid-refractory or -dependent ulcerative colitis using contrast-enhanced ultrasonographyScandinavian Journal of Gastroenterology, 2009
- Crohn's disease and color Doppler sonography: Response to treatment and its relationship with long‐term prognosisJournal of Clinical Ultrasound, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Ultrasonography in the Evaluation of Extension, Activity, and Follow-up of Ulcerative ColitisScandinavian Journal of Gastroenterology, 1999